Skip to main content

Advertisement

SpringerLink
Log in

Analysis of clinical factors contributing to the postglucagon increment in C-peptide levels in Japanese patients with type 2 diabetes: comparison with basal C-peptide levels and 24-h urinary C-peptide excretion

  • Original article
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

We investigated the clinical factors that affected routine laboratory tests of C-peptide levels (CPR) used for the evaluation of β-cell function in Japanese patients with type 2 diabetes. The study subjects were 215 Japanese patients with type 2 diabetes admitted to Juntendo University Hospital just for glycemic control. β-cell function was evaluated by ΔCPR (6-min postglucagon increment in CPR), CPR index (100 × fasting CPR divided by fasting glucose), and 24-h urinary CPR excretion (U-CPR). Stepwise multiple regression analyses of relationships between clinical parameters and these laboratory tests were carried out. The analysis identified BMI and treatment with insulin before admission, but not glycosylated hemoglobin at admission, as independent determinants of all β-cell function tests [BMI: Stdβ (standard regression coefficient) = 0.337, P < 0.01 for ΔCPR, Stdβ = 0.365, P < 0.01 for CPR index, and Stdβ = 0.207, P < 0.01 for U-CPR, and treatment with insulin before admission: Stdβ = −0.141, P = 0.023 for ΔCPR, Stdβ = −0.285, P < 0.01 for CPR index, and Stdβ = −0.258, P < 0.01 for U-CPR]. The estimated glomerular filtration rate (eGFR) was an independent determinant of U-CPR (Stdβ = 0.145, P = 0.023), but not ΔCPR. In conclusion, ΔCPR evaluates β-cell function without being affected by eGFR and glycemic control over the preceding 2–3 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care. 2011;34(Suppl 2):S202–9.

    Article  PubMed  Google Scholar 

  2. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes. 1995; 44:1249–58.

    Google Scholar 

  3. Aoki Y. Variation of endogenous insulin secretion in association with treatment status: assessment by serum C-peptide and modified urinary C-peptide. Diabetes Res Clin Pract. 1991;14:165–73.

    Article  PubMed  CAS  Google Scholar 

  4. Goto A, Takaichi M, Kishimoto M, Takahashi Y, Kajio H, Shimbo T, Noda M. Body mass index, fasting plasma glucose levels, and C-peptide levels as predictors of the future insulin use in Japanese type 2 diabetic patients. Endocr J. 2010;57:237–44.

    Article  PubMed  CAS  Google Scholar 

  5. Siraj ES, Reddy SS, Scherbaum WA, Abdulkadir J, Hammel JP, Faiman C. Basal and postglucagon C-peptide levels in Ethiopians with diabetes. Diabetes Care. 2002;25:453–7.

    Google Scholar 

  6. Hendriksen C, Faber OK, Drejer J, Binder C. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon. Diabetologia. 1977;13:615–9.

    Article  PubMed  CAS  Google Scholar 

  7. Matsuda A, Kamata I, Iwamoto Y, Sakamoto Y, Kuzuya T. A comparison of serum C-peptide response to intravenous glucagon, and urine C-peptide, as indexes of insulin dependence. Diabetes Res Clin Pract. 1985;1:161–7.

    Article  PubMed  CAS  Google Scholar 

  8. Koskinen PJ, Viikari JS, Irjala KM. Glucagon-stimulated and postprandial plasma C-peptide values as measures of insulin secretory capacity. Diabetes Care. 1988;11:318–22.

    Article  PubMed  CAS  Google Scholar 

  9. Gjessing HJ, Matzen LE, Faber OK, Frøland A. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia. 1989;32:305–11.

    Article  PubMed  CAS  Google Scholar 

  10. Funakoshi S, Fujimoto S, Hamasaki A, Fujiwara H, Fujita Y, Ikeda K, Hamamoto Y, Hosokawa M, Seino Y, Inagaki N. Analysis of factors influencing pancreatic beta-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic exposure. Diabetes Res Clin Pract. 2008;82:353–8.

    Article  PubMed  CAS  Google Scholar 

  11. Zavaroni I, Deferrari G, Lugari R, Bonora E, Garibotto G, Dall’Aglio E, Robaudo C, Gnudi A. Renal metabolism of C-peptide in man. J Clin Endocrinol Metab. 1987;65:494–8.

    Article  PubMed  CAS  Google Scholar 

  12. ten Dam MA, Werter CJ, Popp-Snijders C, Donker AJ, ten Kate RW. Renal handling of insulin and C-peptide in patients with non-insulin-dependent diabetes mellitus. Nephrol Dial Transpl. 1993;8:134–9.

    Google Scholar 

  13. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.

    Article  PubMed  CAS  Google Scholar 

  14. The Committee on the standardization of diabetes mellitus-related laboratory testing of the Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int. 2012;3:8–10.

    Google Scholar 

  15. Taniguchi A, Fukushima M, Sakai M, Kataoka K, Nagata I, Doi K, Arakawa H, Nagasaka S, Tokuyama K, Nakai Y. The role of the body mass index and triglyceride levels in identifying insulin-sensitive and insulin-resistant variants in Japanese non-insulin-dependent diabetic patients. Metabolism. 2000;49:1001–5.

    Article  PubMed  CAS  Google Scholar 

  16. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–10.

    Article  PubMed  CAS  Google Scholar 

  17. Yoon KH, Ko SH, Cho JH, Lee JM, Ahn YB, Song KH, Yoo SJ, Kang MI, Cha BY, Lee KW, Son HY, Kang SK, Kim HS, Lee IK, Bonner-Weir S. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab. 2003;88:2300–8.

    Article  PubMed  CAS  Google Scholar 

  18. Aoki Y, Yanagisawa Y, Oguchi H, Furuta S. Contribution of hyperglycemia and renal damage to urinary C-peptide clearance in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract. 1991;14:85–9.

    Article  PubMed  CAS  Google Scholar 

  19. Iseki K. Chronic kidney disease in Japan. Intern Med. 2008;47:681–9.

    Article  PubMed  Google Scholar 

  20. Matsuzawa Y. The role of fat topology in the risk of disease. Int J Obes (Lond). 2008;32(Suppl 7):S83–92.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank all the staff at the Department of Medicine, Metabolism and Endocrinology, Juntendo University Graduate School of Medicine.

Conflict of interest

The authors declare that this study has no financial support or relationships that may pose a conflict of interest.

Author information

Authors and Affiliations

  1. Department of Medicine, Metabolism, and Endocrinology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan

    Akio Kanazawa, Masako Tokoro, Fuki Ikeda, Chie Ohmura, Fumihiko Sato, Yoshio Fujitani & Hirotaka Watada

  2. The Center for Molecular Diabetology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan

    Hirotaka Watada

  3. The Center for Therapeutic Innovations in Diabetes, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan

    Akio Kanazawa, Yoshio Fujitani & Hirotaka Watada

  4. The Sportology Center, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan

    Ryuzo Kawamori & Hirotaka Watada

  5. The Center for Beta Cell Biology and Regeneration, Juntendo University Graduate School of Medicine, Tokyo, Japan

    Hirotaka Watada

Authors
  1. Akio Kanazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masako Tokoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fuki Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chie Ohmura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fumihiko Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshio Fujitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ryuzo Kawamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hirotaka Watada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akio Kanazawa.

About this article

Cite this article

Kanazawa, A., Tokoro, M., Ikeda, F. et al. Analysis of clinical factors contributing to the postglucagon increment in C-peptide levels in Japanese patients with type 2 diabetes: comparison with basal C-peptide levels and 24-h urinary C-peptide excretion. Diabetol Int 4, 60–65 (2013). https://doi.org/10.1007/s13340-012-0097-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-012-0097-4

Keywords

Search

Navigation